Pfizer will offer as much as $4B for Ratiopharm, sources say

03/3/2010 | Wall Street Journal, The

Pfizer is preparing to offer as much as $4 billion to acquire generic-drug firm Ratiopharm, putting the company in competition with Actavis and Teva Pharmaceutical Industries, sources said. A Pfizer spokesman declined to comment. The bid reportedly would include extra funding for Ratiopharm's research and development.

View Full Article in:

Wall Street Journal, The